On June 23, 2024, the Board of Directors of Bellevue Life Sciences Acquisition Corp. appointed Mr. Sang Hyun Kim as a director, effective immediately. Mr. Kim was appointed as a member of the Audit Committee of the BLAC Board, filling the vacancy created by the resignation of Inchul Chung, as previously reported by BLAC on Form 8-K filed with the SEC on June 13, 2024.

Additionally, Mr. Kim was appointed as a member of the Compensation Committee of the BLAC Board and a member of the M&A Committee, filling vacancies created by the resignation of Mr. Radclyffe Roberts as previously reported on the June 13 Form 8-K. Mr. Kim, 53, currently serves as the Special Advisor of Marketing, Private Equity Funds at Korea Daesung Asset Management Co. Ltd. the position held by him since January 2021. Prior to that, Mr. Kim has spent approximately 11 years working in different positions with Samsung Group including, most recently, as part of the Global M&A Strategy Team at Samsung Asset Management HQ from January 2020 to December 2020.

He also served as CEO, Regional Managing Director at Samsung Asset Management Beijing Ltd. from October 2016 to December 2019, Chief Strategy Officer & Global Business Development Officer at Samsung Asset Management HQ from April 2013 to September 2016, and Senior Principal, Corporate Planning and Strategy Department at Samsung Fire and Marine Insurance from January 2010 to March 2013. Mr. Kim earned his MBA degree from Georgetown University in 2001, and his M.A. (Public Policy) and B.S. (International Economics) from Seoul National University. BLAC believes Mr. Kim is well qualified to serve as a director because of his extensive experience in both legal and investment sectors across various asset classes, demonstrating significant expertise in capital markets.